Genmab locked in J&J royalty payments dispute
24-09-2020
Gilead to buy Immunomedics for $21bn
14-09-2020
Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal
03-08-2020
J&J wants $25m over ‘contaminated’ fake medical tools
29-06-2020
sundryphotography / Shutterstock.com
Johnson & Johnson (J&J) is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Johnson & Johnson, J&J, Momenta Pharmaceuticals, Sanofi, Principia Biopharma, M&A, mergers and acquisitions, autoimmune, biotech
